Investigational Drug Information for Larazotide
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the development status for investigational drug Larazotide?
Larazotide is an investigational drug.
There have been 9 clinical trials for Larazotide.
The most recent clinical trial was a Phase 2 trial, which was initiated on May 29th 2019.
The most common disease conditions in clinical trials are Celiac Disease, Syndrome, and COVID-19. The leading clinical trial sponsors are 9 Meters Biopharma, Inc., Alba Therapeutics, and Teva Pharmaceuticals USA.
There are two US patents protecting this investigational drug and thirty-six international patents.
Summary for Larazotide
US Patents | 2 |
International Patents | 36 |
US Patent Applications | 38 |
WIPO Patent Applications | 29 |
Japanese Patent Applications | 10 |
Clinical Trial Progress | Phase 2 (2019-05-29) |
Vendors | 12 |
Recent Clinical Trials for Larazotide
Title | Sponsor | Phase |
---|---|---|
AT1001 for the Treatment of COVID-19 Related MIS-C | Massachusetts General Hospital | Phase 2 |
Study to Evaluate the Efficacy and Safety of Larazotide Acetate for the Relief of CeD Symptoms | 9 Meters Biopharma, Inc. | Phase 3 |
Study to Evaluate the Efficacy and Safety of Larazotide Acetate for the Relief of CeD Symptoms | Innovate Biopharmaceuticals | Phase 3 |
Clinical Trial Summary for Larazotide
Top disease conditions for Larazotide
Top clinical trial sponsors for Larazotide
US Patents for Larazotide
Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
---|---|---|---|---|
Larazotide | See Plans and Pricing | Gluten-related disorders | H.J. Heinz Company Brands LLC (Pittsburgh, PA) | See Plans and Pricing |
Larazotide | See Plans and Pricing | Larazotide acetate compositions | Alba Therapeutics Corporation (Baltimore, MD) | See Plans and Pricing |
>Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Larazotide
Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
---|---|---|---|---|
Larazotide | Australia | AU2013277316 | 2032-06-18 | See Plans and Pricing |
Larazotide | Australia | AU2018203543 | 2032-06-18 | See Plans and Pricing |
Larazotide | Brazil | BR112014031666 | 2032-06-18 | See Plans and Pricing |
>Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |